Ilya Goldshleger Sells 3,105 Shares of RxSight, Inc. (NASDAQ:RXST) Stock

RxSight, Inc. (NASDAQ:RXST) insider Ilya Goldshleger sold 3,105 shares of the stock in a transaction that occurred on Wednesday, October 30th. The stock was sold at an average price of $51.91, for a total value of $161,180.55. Following the sale, the insider now directly owns 42,246 shares in the company, valued at $2,192,989.86. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Ilya Goldshleger also recently made the following trade(s):

• On Friday, October 25th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $49.79, for a total value of $154,349.00.
• On Monday, October 28th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $50.64, for a total value of $156,984.00.
• On Tuesday, October 22nd, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $49.68, for a total value of $154,008.00.
• On Friday, October 18th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The shares were sold at an average price of $50.09, for a total value of $155,529.45.
• On Wednesday, October 16th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $49.78, for a total value of $154,318.00.
• On Friday, October 11th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $50.19, for a total value of $155,589.00.
• On Monday, October 14th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $50.09, for a total value of $155,279.00.
• On Tuesday, October 8th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $48.26, for a total value of $149,606.00.
• On Friday, October 4th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $48.01, for a total value of $148,831.00.
• On Monday, September 30th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $49.02, for a total value of $151,962.00.

RxSight Stock Up 0.9 %

Shares of NASDAQ:RXST opened at $51.10 on Friday. The firm has a market cap of $1.89 billion, a P/E ratio of -50.10 and a beta of 1.20. RxSight, Inc. has a 12-month low of $22.60 and a 12-month high of $66.54. The business has a fifty day simple moving average of $51.65 and a 200 day simple moving average of $53.60.

RxSight (NASDAQ:RXST) last announced its earnings results on Monday, August 5th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.06. The business had revenue of $34.89 million during the quarter, compared to analyst estimates of $32.33 million. RxSight had a negative return on equity of 19.33% and a negative net margin of 31.92%. RxSight’s revenue for the quarter was up 67.6% compared to the same quarter last year. During the same period last year, the company earned ($0.40) EPS. As a group, equities research analysts expect that RxSight, Inc. will post -0.81 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Principal Financial Group Inc. grew its holdings in RxSight by 0.7% during the 3rd quarter. Principal Financial Group Inc. now owns 36,046 shares of the company’s stock worth $1,782,000 after acquiring an additional 240 shares during the period. Arista Wealth Management LLC acquired a new stake in RxSight during the 3rd quarter worth about $258,000. Nisa Investment Advisors LLC grew its holdings in RxSight by 854.1% during the 3rd quarter. Nisa Investment Advisors LLC now owns 582 shares of the company’s stock worth $29,000 after acquiring an additional 521 shares during the period. Sara Bay Financial grew its holdings in RxSight by 0.8% during the 3rd quarter. Sara Bay Financial now owns 108,853 shares of the company’s stock worth $5,381,000 after acquiring an additional 832 shares during the period. Finally, Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in RxSight during the 2nd quarter worth about $3,670,000. 78.78% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have recently commented on RXST shares. Needham & Company LLC reiterated a “buy” rating and issued a $66.00 price target on shares of RxSight in a research note on Friday, September 13th. Jefferies Financial Group started coverage on RxSight in a research note on Tuesday. They issued a “buy” rating and a $72.00 price target for the company. Stifel Nicolaus dropped their price target on RxSight from $70.00 to $65.00 and set a “buy” rating for the company in a research note on Tuesday, August 6th. Wells Fargo & Company dropped their price target on RxSight from $68.00 to $54.00 and set an “overweight” rating for the company in a research note on Tuesday, August 6th. Finally, BTIG Research increased their price target on RxSight from $72.00 to $73.00 and gave the company a “buy” rating in a research note on Monday, July 15th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $61.63.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.